As the voice for women with ovarian cancer on Capitol Hill, OCRFA fights to secure funding for ovarian cancer research and education at the federal level. In 2016, with the help of committed Advocate Leaders, Grassroots Advocates, Research Advocates and action alert supporters, OCRFA was able to: We’ve made great strides in ensuring that ovarian … Continued
OCRFA-funded scientists are working hard to save women’s lives. In medical institutions across the country, they investigate the origins and biology of ovarian cancer, find new ways to identify and prevent the disease, and discover better treatments. In 2016, our grantees made significant advances in the fight against ovarian cancer, including: Progress is being made … Continued
Tickets are now available for the 2017 Turn Up the Heat! Gala in Washington DC. Turn Up the Heat features food from the top female chefs in DC and the surrounding area! Join us on February 22nd for a night full of delicious food and great company. Get your tickets at www.turnuptheheatgala.org
The Kolker Fellowship commemorates the legacy of pioneering health policy advocate Ann Kolker. At the time Ann was diagnosed with ovarian cancer in 1996, she was already a political powerhouse, having early involvement with organizations like the National Women’s Political Caucus and Emily’s List. We are now accepting applications for the Fall 2017 Fellowship.
(Dec. 9, 2016) This week Genentech announced that the US Food and Drug Administration has expanded approval for bevacizumab (Avastin) to include patients with platinum-sensitive, recurrent disease, either in combination with carboplatin and paclitaxel or in combination with carboplatin and gemcitabine chemotherapy, followed by Avastin alone. The approval is based on two large Phase III … Continued
Recurrence is in the back of every ovarian cancer survivor’s mind. In this presentation, originally broadcast on November 28, 2016, Dr. Sarah Adams provided an overview of strategies for managing recurrent ovarian cancer, discussing the goals of treatment during recurrence, typical courses of treatment, and advice on how to approach making decisions about treatment during … Continued
OCRFA recently welcomed four new members to the Scientific Advisory Committee (SAC), our world-class group of leaders in the ovarian cancer field who review and approve all OCRFA research grants. Ronald Alvarez, MD, MBA, of Vanderbilt University Medical Center, Deborah Armstrong, MD, of Johns Hopkins School of Medicine, Robert Coleman, MD, of M.D. Anderson Cancer … Continued
(Nov. 3, 2016) Senescence is the state when normal, healthy cells no longer have the ability to divide, which can occur during chemotherapy or when cancer genes within that cell are activated. Senescence can be very useful, for example, when one wants to stop cancer cells from rapidly dividing, but there can be negative side … Continued
(October 31, 2016) Estrogen signaling is a known factor in how certain estrogen receptive (ER positive) tumors grow in breast and ovarian cancers. That signaling, which can promote malignant tumor growth, can sometimes be effectively treated with anti-estrogen therapy, such as tamoxifen. What is less understood, and currently being studied at the Wistar Institute, is … Continued
We’re excited to announce that OCRFA’s new and refreshed website is live. The new site is reflective of the merger of Ovarian Cancer Research Fund and the Ovarian Cancer National Alliance to become Ovarian Cancer Research Alliance or OCRFA, the largest and oldest non-profit organization dedicated to advancing cancer research, while supporting women and their … Continued
On September 7th, the FDA issued an important safety communication about tests marketed as ovarian cancer screening tests, including the ROCA Test developed by Abcodia Incorporated. The FDA states, “despite extensive research and published studies, there are currently no screening tests for ovarian cancer that are sensitive enough to reliably screen for ovarian cancer without a … Continued
A Mayo Clinic research team has found evidence suggesting that premenopausal women who are not at high risk of ovarian cancer should not have their ovaries removed for the purpose of cancer prevention. Premature removal of the ovaries can lead to a higher risk of anywhere from 8 to 18 chronic health conditions including coronary … Continued
Get email updates about research news, action alerts, and ways to join the fight.
